Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Arcus Biosciences Inc. (RCUS)

25.6568   0.337 (1.33%) 07-08 10:33
Open: 25.42 Pre. Close: 25.32
High: 25.83 Low: 24.65
Volume: 91,073 Market Cap: 1,181M
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer therapies in the United States. The company's product pipeline includes, AB928, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 monoclonal antibody that is in Phase Ib clinical trial for monotherapy. It is also developing AB154, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab and AB928; and AB680, small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer. Arcus Biosciences, Inc. has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics (Cayman) Inc.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 25.594 - 25.718 25.718 - 25.825
Low: 23.537 - 23.674 23.674 - 23.791
Close: 25.106 - 25.328 25.328 - 25.519

Technical analysis

as of: 2020-07-08 10:02:03 AM
Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 35.11     One year: 40.81
Support: Support1: 22.16    Support2: 18.43
Resistance: Resistance1: 30.06    Resistance2: 34.94
Pivot: 24.90
Moving Average: MA(5): 24.36     MA(20): 25.84
MA(100): 22.89     MA(250): 14.31
MACD: MACD(12,26): -1.27     Signal(9): -1.30
Stochastic oscillator: %K(14,3): 35.17     %D(3): 28.62
RSI: RSI(14): 44.96
52-week: High: 37.41  Low: 6.30  Change(%): 193.8
Average Vol(K): 3-Month: 95848  10-Days: 85689

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently below mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
RCUS has closed below upper band by 47.6%. Bollinger Bands are 49.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to RCUS's normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.

Headline News

Tue, 07 Jul 2020
Bob Goeltz to Join Arcus Biosciences as Chief Financial Officer - Business Wire

Thu, 02 Jul 2020
Strong fundamental momentum pushes Arcus Biosciences, Inc. (RCUS) higher - Marketing Sentinel

Mon, 29 Jun 2020
Has Arcus Biosciences (RCUS) Outpaced Other Medical Stocks This Year? - Yahoo Finance

Tue, 23 Jun 2020
Here is why Arcus Biosciences, Inc. (RCUS) recent weekly performance of -11.90% shouldn’t bother you at All - The InvestChronicle

Wed, 17 Jun 2020
Hedge Funds Have Never Been This Bullish On Arcus Biosciences, Inc. (RCUS) - Yahoo Finance

Sun, 14 Jun 2020
Arcus Biosciences (NYSE:RCUS) Upgraded by Zacks Investment Research to Buy - Stock Market Daily

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Click here to get more fundamental analysis.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  New York Stock Exchange
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 46
Shares Float (M) 30
% Held by Insiders 28.97
% Held by Institutions 53.08
Shares Short (K) 1,670
Shares Short P. Month (K) 425

Stock Financials

EPS -2.150
EPS Est This Year
EPS Est Next Year
Book Value (p.s.) 3.060
Profit Margin
Operating Margin -655.57
Return on Assets (ttm) -28.3
Return on Equity (ttm) -52.3
Qtrly Rev. Growth
Gross Profit (p.s.) -1.379
Sales Per Share 0.326
EBITDA (p.s.) -2.060
Qtrly Earnings Growth
Operating Cash Flow (M) -88
Levered Free Cash Flow (M) -52

Stock Valuations

PE Ratio -11.64
PEG Ratio
Price to Book value 8.18
Price to Sales 76.84
Price to Cash Flow -13.11

Stock Dividends

Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2020 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.